These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30824168)

  • 1. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
    Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of 7-methylimidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD4 inhibitors.
    Zhao L; Yang Y; Guo Y; Yang L; Zhang J; Zhou J; Zhang H
    Bioorg Med Chem; 2017 Apr; 25(8):2482-2490. PubMed ID: 28314513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor.
    Martin LJ; Koegl M; Bader G; Cockcroft XL; Fedorov O; Fiegen D; Gerstberger T; Hofmann MH; Hohmann AF; Kessler D; Knapp S; Knesl P; Kornigg S; Müller S; Nar H; Rogers C; Rumpel K; Schaaf O; Steurer S; Tallant C; Vakoc CR; Zeeb M; Zoephel A; Pearson M; Boehmelt G; McConnell D
    J Med Chem; 2016 May; 59(10):4462-75. PubMed ID: 26914985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family.
    Yang Y; Chen P; Zhao L; Zhang F; Zhang B; Xu C; Zhang H; Zhou J
    Bioorg Chem; 2019 Sep; 90():103044. PubMed ID: 31220668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
    Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
    J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.
    Cui S; Wang Y; Wang Y; Tang X; Ren X; Zhang L; Xu Y; Zhang Z; Zhang ZM; Lu X; Ding K
    Eur J Med Chem; 2019 Oct; 179():470-482. PubMed ID: 31271959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.
    Hui M; Jian Z; Peiyuan Z; Zhenwei W; Huibin Z
    Future Med Chem; 2018 Apr; 10(8):895-906. PubMed ID: 29620420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.
    Crawford TD; Vartanian S; Côté A; Bellon S; Duplessis M; Flynn EM; Hewitt M; Huang HR; Kiefer JR; Murray J; Nasveschuk CG; Pardo E; Romero FA; Sandy P; Tang Y; Taylor AM; Tsui V; Wang J; Wang S; Zawadzke L; Albrecht BK; Magnuson SR; Cochran AG; Stokoe D
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3534-3541. PubMed ID: 28606761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
    Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
    Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.
    Remillard D; Buckley DL; Paulk J; Brien GL; Sonnett M; Seo HS; Dastjerdi S; Wühr M; Dhe-Paganon S; Armstrong SA; Bradner JE
    Angew Chem Int Ed Engl; 2017 May; 56(21):5738-5743. PubMed ID: 28418626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines.
    Kamal A; Ramakrishna G; Raju P; Rao AV; Viswanath A; Nayak VL; Ramakrishna S
    Eur J Med Chem; 2011 Jun; 46(6):2427-35. PubMed ID: 21481986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
    Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition.
    Hohmann AF; Martin LJ; Minder JL; Roe JS; Shi J; Steurer S; Bader G; McConnell D; Pearson M; Gerstberger T; Gottschamel T; Thompson D; Suzuki Y; Koegl M; Vakoc CR
    Nat Chem Biol; 2016 Sep; 12(9):672-9. PubMed ID: 27376689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
    Krämer KF; Moreno N; Frühwald MC; Kerl K
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations.
    Song LT; Tu J; Liu RR; Zhu M; Meng YJ; Zhai HL
    J Biomol Struct Dyn; 2019 Jul; 37(11):2970-2979. PubMed ID: 30058436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
    Huang B; Liang X; Li C; Chen W; Liu T; Li X; Sun Y; Fu L; Liu H; De Clercq E; Pannecouque C; Zhan P; Liu X
    Eur J Med Chem; 2015 Mar; 93():330-7. PubMed ID: 25707013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective synthesis of benzimidazoles-imidazo[1,2-a]pyrazine conjugates: A comparative study of mono-and bis-benzimidazoles for antitumor activity.
    Singh I; Luxami V; Paul K
    Eur J Med Chem; 2019 Oct; 180():546-561. PubMed ID: 31344614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
    Karim RM; Chan A; Zhu JY; Schönbrunn E
    J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.
    Marchand P; Bazin MA; Pagniez F; Rivière G; Bodero L; Marhadour S; Nourrisson MR; Picot C; Ruchaud S; Bach S; Baratte B; Sauvain M; Pareja DC; Vaisberg AJ; Le Pape P
    Eur J Med Chem; 2015 Oct; 103():381-95. PubMed ID: 26383125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.